Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke

Inclusion Criteria: 1. 1st cortical or subcortical unilateral infarction (supratentorial lesion) 2. Confirmed by CT or MRI 3. Subacute stage: less than 1 week 4. Moderate to severe motor function involvement-total of FMA: 0-84 5. Age: between 18 and 80 years 6. Inpatients Exclusion Criteria: 1. Progressive or unstable stroke 2. Pre-existing and active major neurological disease 3. Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia 4. A history of significant alcohol or drug abuse in the prior 3 years 5. Advanced liver, kidney, cardiac, or pulmonary disease 6. A terminal medical diagnosis consistent with survival \< 1 year 7. Substantial decrease in alertness at the time of randomization, defined as score of 2 on NIH Stroke Scale 8. Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years 9. Any condition that would represent a contraindication to Cerebrolysin, including allergy to Cerebrolysin 10. Current enrolment in another therapeutic study of stroke or stroke recovery 11. Total serum bilirubin \> 4 mg/dL, alkaline phosphatase \> 250 U/L, SGOT/AST \> 150 U/L, SGPT/ALT \> 150 U/L, or creatinine \> 3.5 mg/dL; or cardiopulmonary deficits large enough to interfere with reasonable participation in physiotherapy during the trial. 12. Previous porcine brain peptide administration history